Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 15-22 , January 2008

Postprostatectomy Radiation Therapy for Prostate Cancer

  • Matthew C. Abramowitz, MD
    • ,
  • Alan Pollack, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Alan Pollack, MD, PhD, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

References 

  1. Forman JD, Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Huntington). 1998;12:33–39discussion 39, 43-44, 47
  2. Schild SE. Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy. Int J Cancer. 2001;96:94–98
  3. Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: Multi-institutional assessment of 5831 patients. Urology. 2005;66:1245–1250
  4. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage (Gleason score, and margin status for localized prostate cancer). Urology. 2003;62:866–871
  5. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: Risk factors for failure and death. Urol Oncol. 2007;25:110–114
  6. Vis AN, Schroder FH, van der Kwast TH. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol. 2006;50:258–265
  7. Dahl DM, He W, Lazarus R, et al. Pathologic outcome of laparoscopic and open radical prostatectomy. Urology. 2006;68:1253–1256
  8. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years. J Urol. 2000;164:101–105
  9. Kupelian PA, Katcher J, Levin HS, et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 1997;37:1043–1052
  10. Tefilli MV, Gheiler EL, Tiguert R, et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol. 1998;160:802–806
  11. Anscher MS, Prosnitz LR. Multivariate analysis of factors predicting local relapse after radical prostatectomy—Possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21:941–947
  12. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483–489
  13. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol. 2004;172:910–914
  14. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332
  15. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA. 2006;296:2329–2335
  16. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  17. Pollack A, Hanlon AL, Pisansky TM, et al. A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004;60(suppl 1):S186–S187
  18. Pazona JF, Han M, Hawkins SA, et al. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol. 2005;174:1282–1286
  19. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–2041
  20. Vicini FA, Ziaja EL, Kestin LL, et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999;54:111–117
  21. Wilder RB, Hsiang JY, Ji M, et al. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am J Clin Oncol. 2000;23:176–180
  22. Mosbacher MR, Schiff PB, Otoole KM, et al. Postprostatectomy salvage radiation therapy for prostate cancer: Impact of pathological and biochemical variables and prostate fossa biopsy. Cancer J. 2002;8:242–246
  23. Morris MM, Dallow KC, Zietman AL, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:731–736
  24. Schild SE, Buskirk SJ, Wong WW, et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 1996;156:1725–1729
  25. Pacholke HD, Wajsman Z, Algood CB, et al. Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology. 2004;64:982–986
  26. Kundel Y, Pfeffer R, Lauffer M, et al. Salvage prostatic fossa radiation therapy for biochemical failure after radical prostatectomy: The Sheba experience. Isr Med Assoc J. 2004;6:329–331
  27. Tsien C, Griffith KA, Sandler HM, et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology. 2003;62:93–98
  28. Cheung R, Kamat AM, de Crevoisier R, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005;63:134–140
  29. Terai A, Matsui Y, Yoshimura K, et al. Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int. 2005;96:1009–1013
  30. MacDonald OK, Schild SE, Vora S, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: Do outcomes differ?. Urology. 2004;64:760–764
  31. Zelefsky MJ, Aschkenasy E, Kelsen S, et al. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39:327–333
  32. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439
  33. Syndikus I, Pickles T, Kostashuk E, et al. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol. 1996;155:1983–1986
  34. Petrovich Z, Lieskovsky G, Stein JP, et al. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int. 2002;89:604–611
  35. Do LV, Do TM, Smith R, et al. Postoperative radiotherapy for carcinoma of the prostate: Impact on both local control and distant disease-free survival. Am J Clin Oncol. 2002;25:1–8
  36. Stein A, deKernion JB, Dorey F, et al. Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology. 1992;39:59–62
  37. Swanson GP. Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794). Int J Radiat Oncol Biol Phys. 2005;63(suppl 1):S1
  38. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus wait and see“ (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95). J Clin Oncol. 2005;23:381;381, (abstr 4513)
  39. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25:4178–4186
  40. Swanson GP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–2229
  41. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–523
  42. Kausik SJ, Blute ML, Sebo TJ, et al. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002;95:1215–1219
  43. Pound C, Partin A, Eisenberger M, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  44. Anscher MS. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer. 2001;96:91–93
  45. Petrovich Z, Lieskovsky G, Langholz B, et al. Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate. Am J Clin Oncol. 2001;24:537–546
  46. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–1507
  47. Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59:51–60
  48. Garg MK, Tekyi-Mensah S, Bolton S, et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 1998;51:998–1002
  49. Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001;19:1030–1039
  50. Chawla AK, Thakral HK, Zietman AL, et al. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: Analysis of efficacy and prognostic factors. Urology. 2002;59:726–731
  51. Lee AK, D’Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol. 2005;23:8192–8197
  52. D’Amico AV, Chen MH, Roehl KA, et al. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol. 2005;23:4975–4979
  53. Taylor N, Kelly JF, Kuban DA, et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;56:755–763
  54. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys. 2000;48:369–375
  55. Valicenti RK, Gomella LG, Ismail M, et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:501–506
  56. Macdonald OK, Schild SE, Vora SA, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003;170:1833–1837
  57. Cox J, Gallagher M, Hammond E, et al. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels and radical prostatectomy (American Society for Therapeutic Radiology and Oncology Consensus Panel). J Clin Oncol. 1999;17:1155–1163
  58. Parker C, Sydes MR, Catton C, et al: Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int (in press)
  59. Petrovich Z, Lieskovsky G, Langholz B, et al. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:600–609
  60. Vargas C, Kestin LL, Weed DW, et al. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys. 2005;61:714–724
  61. Valicenti RK, Gomella LG, Ismail M, et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys. 1999;45:53–58
  62. Valicenti RK, Gomella LG, Ismail M, et al. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: Effect of early adjuvant radiation therapy on biochemical control. Cancer. 1998;82:1909–1914
  63. Leibovich BC, Engen DE, Patterson DE, et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000;163:1178–1182
  64. Kalapurakal JA, Huang CF, Neriamparampil MM, et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002;54:1047–1054
  65. Choo R, Hruby G, Hong J, et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: To irradiate or not?. Int J Radiat Oncol Biol Phys. 2002;52:674–680
  66. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  67. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  68. D’Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA. 2004;292:821–827
  69. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  70. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  71. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  72. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791–794
  73. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167:112–116
  74. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  75. Eulau SM, Tate DJ, Stamey TA, et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998;41:735–740
  76. Tiguert R, Rigaud J, Lacombe L, et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 2003;170:447–450
  77. Neulander EZ. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 2004;171:809–810
  78. King CR, Presti JC, Gill H, et al. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys. 2004;59:341–347
  79. Corn BW, Winter K, Pilepich MV. Does androgen suppression enhance the efficacy of postoperative irradiation? (A secondary analysis of RTOG 85-31). Radiation Therapy Oncology Group Urology. 1999;54:495–502
  80. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005;23:800–807
  81. RTOG Trial 96-01: A phase III trial of radiation therapy with or without Casodex in patients with PSA elevation following radical prostatectomy for pT3N0 carcinoma of the prostate. http://www.rtog.org/Accessed March 13, 2007
  82. RTOG. Trial P-0011: Phase III randomized study of adjuvant therapy for high risk pT2-3N0 prostate cancer. http://www.rtog.org/Accessed March 13, 2007
  83. Foster LS, Jajodia P, Fournier G, et al. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 1993;149:1024–1028
  84. Saleem MD, Sanders H, Abu El Naser M, et al. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology. 1998;51:283–286
  85. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: Correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219:432–439
  86. Scattoni V, Roscigno M, Raber M, et al. Multiple vesico-urethral biopsies following radical prostatectomy: The predictive roles of TRUS. DRE, PSA and the pathological stage Eur Urol. 2003;44:407–414
  87. Naya Y, Okihara K, Evans RB, et al. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology. 2005;66:350–355
  88. Sanguineti G, Castellone P, Foppiano F, et al. Anatomic variations due to radical prostatectomy (Impact on target volume definition and dose-volume parameters of rectum and bladder). Strahlenther Onkol. 2004;180:563–572
  89. Fiorino C, Foppiano F, Franzone P, et al. Rectal and bladder motion during conformal radiotherapy after radical prostatectomy. Radiother Oncol. 2005;74:187–195
  90. Kupelian PA, Langen KM, Willoughby TR, et al. Daily variations in the position of the prostate bed in patients with prostate cancer receiving postoperative external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2006;66:593–596
  91. Schiffner DC, Gottschalk AR, Lometti M, et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67:610–619
  92. Paskalev K, Feigenberg S, Jacob R, et al. Target localization for post-prostatectomy patients using CT and ultrasound image guidance. J Appl Clin Med Phys. 2005;6:40–49
  93. Kim BS, Lashkari A, Vongtama R, et al. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer. 2004;3:93–97
  94. Cozzarini C, Bolognesi A, Ceresoli GL, et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: A single institute experience of 415 patients. Int J Radiat Oncol Biol Phys. 2004;59:674–683
  95. Proano JM, Sodee DB, Resnick MI, et al. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol. 2006;175:1668–1672
  96. Bastasch MD, Teh BS, Mai WY, et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: Effect on erectile function. Int J Radiat Oncol Biol Phys. 2002;54:101–106
  97. Pinkawa M, Siluschek J, Gagel B, et al. Postoperative radiotherapy for prostate cancer: Evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther Onkol. 2007;183:23–29
  98. Morr J, DiPetrillo T, Tsai JS, et al. Implementation and utility of a daily ultrasound-based localization system with intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:1124–1129
  99. Chinnaiyan P, Tomee W, Patel R, et al. 3D-ultrasound guided radiation therapy in the post-prostatectomy setting. Technol Cancer Res Treat. 2003;2:455–458
  100. Scarbrough TJ, Golden NM, Ting JY, et al. Comparison of ultrasound and implanted seed marker prostate localization methods: Implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:378–387
  101. Paskalev K, Ma C-M, Jacob R, et al. Daily target localization for prostate patients based on 3D image correlation. Phys Med Biol. 2004;49:931–939
  102. Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1417–1423
  103. Van Cangh PJ, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: Results of a prospective randomized study. J Urol. 1998;159:164–166
  104. Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163:845–850

PII: S1053-4296(07)00075-6

doi: 10.1016/j.semradonc.2007.09.003

Seminars in Radiation Oncology
Volume 18, Issue 1 , Pages 15-22 , January 2008

Article Tools

* Image Usage & Resolution